047920 — HLB Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapFalling Star

Annual income statement for HLB Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	40,571	62,853	107,482	135,953	137,082
Cost of Revenue
Gross Profit	22,349	35,356	64,008	82,985	86,581
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	42,651	62,367	113,899	141,398	147,823
Operating Profit	-2,080	486	-6,417	-5,445	-10,741
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-92,483	-12,817	-10,952	-18,851	1,166
Provision for Income Taxes
Net Income After Taxes	-74,840	-13,226	-11,777	-19,427	2,020
Net Income Before Extraordinary Items
Net Income	-74,840	-13,226	-11,777	-19,427	2,020
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-74,840	-13,226	-11,777	-19,427	2,020
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-4,617	-572	-432	-976	300
Dividends per Share